Dr. Cahill has more than 29 years of experience in the development of pharmaceutical and immunodiagnostic products. He specializes in developing formulations and preparing the technical documents required for FDA approval of biological and conventional sterile products, including parenteral and novel dosage forms of peptides, proteins, and small molecules. Therapeutic areas of expertise include oncology, ophthalmic diseases, immunomodulation, asthma, antivirals, analgesics, nutritionals, and hormone replacement. He is also experienced in directing pharmaceutical products through all phases of the development process, including formulation, process validation, and scale-up. At Cato Research, Dr. Cahill is responsible for managing the pharmaceutical product development processes, preparing the technical documentation for regulatory submissions, and auditing and selecting manufacturers of clinical trial material. He is also responsible for the development and execution of regulatory and manufacturing strategies for biologics and drugs. In addition, Dr. Cahill participates in the design and conduct of current cGMP and cGLP audits of contract analytical, formulation, and manufacturing firms. Prior to joining Cato Research, Dr. Cahill founded International Diagnostics Inc., where he developed one of the first over-the-counter pregnancy tests. He was responsible for sterile and parenteral product development at Armour and Rorer Pharmaceutical Companies and was Director of Scientific Affairs for Elkins-Sinn, Inc., a division of American Home Products. |